The LRP1 pathway has produced Angiopep 2, a peptide conjugated to chemotherapeutics that demonstrated high BBB influx rates in preclinical studies
Other factors can also contribute to reduced workout performance, including: Low total calorie intake Dehydration Nausea or gastrointestinal discomfort Sleep disruption Dose escalation periods Reduced recovery capacity between sessions The result is often a body that is physically capable of movement, but no longer fully fueled to support the same training output
This makes the case especially relevant to self-funded plan sponsors
The question of which specific GLP-1 medication to start with, and whether compounded or brand-name is the right fit, is worth discussing with a provider who specializes in this area
In terms of safety, the overall rate of adverse events was highest with semaglutide 2.4 mg, followed by liraglutide 3.0 mg, liraglutide 1.8 mg, and semaglutide 1.0m g, compared to placebo
Wegovy is not covered by the PAP in any form